Market Research Report
Methicillin-Resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026
|Published by||GlobalData||Product code||633249|
|Published||Content info||49 Pages
Delivery time: 1-2 business days
|Methicillin-Resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026|
|Published: March 29, 2018||Content info: 49 Pages||
Methicillin-resistant Staphylococcus aureus (MRSA) is a widespread Gram-positive bacterium spread through direct contact with infected individuals. It is characterized by multiple drug resistance to beta-lactam antibiotics, including methicillin, penicillin, and oxacillin.
The MRSA pipeline features 226 products across all stages of clinical development, with the heaviest development in Discovery and Preclinical stages. Emerging early-stage pipeline products include cytolysins, synthetic peptides, and monoclonal antibodies (mAbs). MRSA is the sixth most investigated indication within infectious diseases with 875 clinical trials, trailing malaria (1,160) and influenza (1,603). HIV is first with 5,234 trials.
Overall, GlobalData expects new drug approvals and key patent expiries to drive MRSA market growth over the next decade (2016-2026).In particular, this report provides an in-depth analysis of the following -
Companies mentioned in this report:Allergan, Merck & Co., The Medicines Company, Sanofi, Pfizer, Theravance Biopharma, Kyorin Pharmaceuticals, Melinta Therapeutics, Atox Bio Ltd, Paratek Pharmaceuticals, Bayer AG, Nabriva Therapeutics, Motif BioSciences, Melinta Therapeutics, MicuRx Pharmaceuticals, Citius Pharmaceuticals, TaiGen Biotechnology and Basilea Pharmaceuticals
GlobalData's Methicillin-resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -